These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28970021)

  • 1. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.
    Amato D; Vernon AC; Papaleo F
    Neurosci Biobehav Rev; 2018 Feb; 85():146-159. PubMed ID: 28970021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
    Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
    J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the dopamine D2 receptor in schizophrenia.
    Seeman P
    Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-evoked dopamine supersensitivity.
    Servonnet A; Samaha AN
    Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrastriatal dopamine D
    Nørbak-Emig H; Pinborg LH; Raghava JM; Svarer C; Baaré WFC; Allerup P; Friberg L; Rostrup E; Glenthøj B; Ebdrup BH
    World J Biol Psychiatry; 2017 Oct; 18(7):539-549. PubMed ID: 27782768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy.
    Pani L; Pira L; Marchese G
    Eur Psychiatry; 2007 Jul; 22(5):267-75. PubMed ID: 17419008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.
    Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S
    J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dopamine D(2) receptors for antipsychotic activity.
    Ginovart N; Kapur S
    Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.
    Silvestri S; Seeman MV; Negrete JC; Houle S; Shammi CM; Remington GJ; Kapur S; Zipursky RB; Wilson AA; Christensen BK; Seeman P
    Psychopharmacology (Berl); 2000 Oct; 152(2):174-80. PubMed ID: 11057521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique pharmacological profile of aripiprazole as the phasic component buster.
    Hamamura T; Harada T
    Psychopharmacology (Berl); 2007 Apr; 191(3):741-3. PubMed ID: 17205315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor homooligomers and heterooligomers in schizophrenia.
    Perreault ML; O'Dowd BF; George SR
    CNS Neurosci Ther; 2011 Feb; 17(1):52-7. PubMed ID: 21199449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
    Inoue A; Nakata Y
    Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.